Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in advanced HCC
NCT03463876Phase 2Completed
- Sponsor
- Hengrui
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Hengrui. Started Mar 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03463876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463876.